Oncolytic viro-immunotherapy holds promise for cancer treatment. While immune activation can be robustly triggered by oncolytic viruses, negative feedback is often upregulated in the tumour microenvironment (TME). Lactate accumulation, signal transducer and activator of transcription 3 (STAT3) activation, indoleamine 2,3-dioxygenase 1 (IDO1) expression, and myeloid-derived suppressor cell (MDSC) infiltration coordinate to shape the immunosuppressive TME.
Representative hepatocellular carcinoma (HCC) cell lines and HCC-bearing mice were treated with oncolytic Newcastle disease virus (NDV), alone or in combination with dichloroacetate (DCA, a pyruvate dehydrogenase kinase (PDK) inhibitor).
We found that infection with oncolytic NDV led to significant induction of the aforementioned suppressive factors. Interestingly, DCA significantly reduced lactate release, STAT3 activation, IDO1 upregulation, and MDSC infiltration in NDV-treated HCC. Consequently, DCA significantly enhanced the antitumour immune responses, leading to improved antitumour efficacy and prolonged survival in mouse models of ascitic and subcutaneous HCC. Furthermore, DCA increased NDV replication in a PDK-1-dependent manner in HCC.
Targeting aerobic glycolysis by DCA improves NDV-mediated viro-immunotherapy in HCC by mitigating immune negative feedback and promoting viral replication. These findings provide a rationale for targeting reprogrammed metabolism together with oncolytic virus-mediated viro-immunotherapy for HCC treatment.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bruix, J., Gores, G. J. & Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844–855 (2014).
Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).
Pol, J., Kroemer, G. & Galluzzi, L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5, e1115641 (2016).
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329–336 (2013).
Zamarin, D. & Palese, P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7, 347–367 (2012).
Mansour, M., Palese, P. & Zamarin, D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015–6023 (2011).
Fiola, C., Peeters, B., Fournier, P., Arnold, A., Bucur, M. & Schirrmacher, V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer 119, 328–338 (2006).
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13, 221–228 (2006).
Schirrmacher, V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother. 54, 587–598 (2005).
Schirrmacher, V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin. Biol. Ther. 15, 1757–1771 (2015).
Schwaiger, T., Knittler, M. R., Grund, C., Roemer-Oberdoerfer, A., Kapp, J. F., Lerch, M. M. et al. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity. Int. J. Cancer 141, 2505–2516 (2017).
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226–232 (2014).
Ricca, J. M., Oseledchyk, A., Walther, T., Liu, C., Mangarin, L., Merghoub, T. et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol. Ther. 26, 1008–1019 (2018).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
Sukumar, M., Roychoudhuri, R. & Restifo, N. P. Nutrient competition: a new axis of tumor immunosuppression. Cell 162, 1206–1208 (2015).
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819 (2007).
Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486–1495 (2013).
Beneteau, M., Zunino, B., Jacquin, M. A., Meynet, O., Chiche, J., Pradelli, L. A. et al. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc. Natl Acad. Sci. USA 109, 20071–20076 (2012).
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z. et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123, 4479–4488 (2013).
Thai, M., Graham, N. A., Braas, D., Nehil, M., Komisopoulou, E., Kurdistani, S. K. et al. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 19, 694–701 (2014).
Li, C., Meng, G., Su, L., Chen, A., Xia, M., Xu, C. et al. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma. Oncotarget 6, 1544–1555 (2015).
Yu, Y., Clippinger, A. J. & Alwine, J. C. Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection. Trends Microbiol. 19, 360–367 (2011).
Dube, M. P. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 31, 1467–1475 (2000).
Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1–6 (2016).
Yang, H., Yamazaki, T., Pietrocola, F., Zhou, H., Zitvogel, L., Ma, Y. et al. STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res. 75, 3812–3822 (2015).
Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905–3916 (2015).
Martin, N. T. & Bell, J. C. Oncolytic virus combination therapy: killing one bird with two stones. Mol. Ther. 26, 1414–1422 (2018).
Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498–513 (2018).
Meng, G., Fei, Z., Fang, M., Li, B., Chen, A., Xu, C. et al. Fludarabine as an adjuvant improves newcastle disease virus-mediated antitumor immunity in hepatocellular carcinoma. Mol. Ther. Oncolytics 13, 22–34 (2019).
Michelakis, E. D., Webster, L. & Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 99, 989–994 (2008).
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E. et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2, 31–34 (2010).
Ohashi, T., Akazawa, T., Aoki, M., Kuze, B., Mizuta, K., Ito, Y. et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int. J. Cancer 133, 1107–1118 (2013).
Chang, C. H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).
Demaria, M. & Poli, V. PKM2, STAT3 and HIF-1alpha: the Warburg’s vicious circle. JAKSTAT 1, 194–196 (2012).
Hanafi, L. A., Gauchat, D., Godin-Ethier, J., Possamai, D., Duvignaud, J. B., Leclerc, D. et al. Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism. PLoS ONE 9, e99211 (2014).
Nie, X. H., Ou-yang, J., Xing, Y., Li, D. Y., Dong, X. Y., Liu, R. E. et al. Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway. Drug Des. Devel. Ther. 9, 5611–5622 (2015).
Mu, X., Shi, W., Xu, Y., Xu, C., Zhao, T., Geng, B. et al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle 17, 428–438 (2018).
Li, W., Tanikawa, T., Kryczek, I., Xia, H., Li, G., Wu, K. et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 28, 87–103 (2018).
Mace, T. A., Ameen, Z., Collins, A., Wojcik, S., Mair, M., Young, G. S. et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73, 3007–3018 (2013).
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13, 412–424 (2015).
Meng, G., Xia, M., Wang, D., Chen, A., Wang, Y., Wang, H. et al. Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget 5, 6365–6374 (2014).
We thank Prof. Y. Wang (Jiangsu Academy of Agricultural Sciences, China) for providing the NDV La Sota strain, and Translational Medicine Core Facilities of Nanjing University for instrumental support.
The authors declare no competing interests.
Ethics approval and consent to participate
All animal experiments were conducted with the approval of the Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School. Animal welfare was closely monitored in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The human HCC cell line HCCLM3 and mouse HCC cell line H22 were acquired from the China Center for Type Culture Collection (Wuhan, China), the mouse HCC cell line Hepa1-6 was acquired from Cell Bank of Type Culture Collection Chinese Academy of Sciences (Shanghai, China).
This work was supported by the National Natural Science Foundation of China (81773255, 81700037, 81871967, and 81903147), the Natural Science Foundation of Jiangsu Province of China (BK20171098), Social Development Foundation of Jiangsu Province of China (BE2018604), Six talent peaks project in Jiangsu Province to J.W., Jiangsu Provincial Medical Talent to D.Y., and Project funded by China Postdoctoral Science Foundation (2018M642223).
Consent to publish
All data and materials generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Meng, G., Li, B., Chen, A. et al. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. Br J Cancer 122, 111–120 (2020). https://doi.org/10.1038/s41416-019-0639-7
Development of cancer metabolism as a therapeutic target: new pathways, patient studies, stratification and combination therapy
British Journal of Cancer (2019)